VEGFRHemmer

VEGFR (Vascular Endothelial Growth Factor Receptor) inhibitors, commonly referred to as VEGFR inhibitors or VEGFR tyrosine kinase inhibitors (TKIs), are a class of drugs used to treat various types of cancer. VEGFRs are proteins found on the surface of cells that play a crucial role in the growth and maintenance of blood vessels. By inhibiting these receptors, VEGFR inhibitors can disrupt the process of angiogenesis, the formation of new blood vessels, which is essential for tumor growth and metastasis.

VEGFR inhibitors are typically used in combination with other therapies, such as chemotherapy or targeted therapies, to enhance their effectiveness. They are often prescribed for advanced or metastatic cancers, including colorectal, lung, and kidney cancers. Some common VEGFR inhibitors include bevacizumab, a monoclonal antibody that blocks VEGF-A, and sunitinib, a small-molecule inhibitor that targets multiple VEGFRs.

The use of VEGFR inhibitors has been associated with significant side effects, including hypertension, proteinuria, and hemorrhage. Therefore, careful monitoring and management of these side effects are essential for the safe and effective use of these drugs. Ongoing research continues to explore the optimal use of VEGFR inhibitors in combination with other therapies to improve patient outcomes and reduce the incidence of side effects.